These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26750096)

  • 1. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
    Olsen JB; Cao XJ; Han B; Chen LH; Horvath A; Richardson TI; Campbell RM; Garcia BA; Nguyen H
    Mol Cell Proteomics; 2016 Mar; 15(3):892-905. PubMed ID: 26750096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
    Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
    J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates.
    Ahmed H; Duan S; Arrowsmith CH; Barsyte-Lovejoy D; Schapira M
    J Proteome Res; 2016 Jun; 15(6):2052-9. PubMed ID: 27163177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
    Weirich S; Schuhmacher MK; Kudithipudi S; Lungu C; Ferguson AD; Jeltsch A
    Chembiochem; 2020 Jan; 21(1-2):256-264. PubMed ID: 31612581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.
    Jiang Y; Trescott L; Holcomb J; Zhang X; Brunzelle J; Sirinupong N; Shi X; Yang Z
    J Mol Biol; 2014 Oct; 426(20):3413-25. PubMed ID: 24594358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
    Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
    Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
    Xu S; Zhong C; Zhang T; Ding J
    J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
    Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
    Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
    Komatsu S; Imoto I; Tsuda H; Kozaki KI; Muramatsu T; Shimada Y; Aiko S; Yoshizumi Y; Ichikawa D; Otsuji E; Inazawa J
    Carcinogenesis; 2009 Jul; 30(7):1139-46. PubMed ID: 19423649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of substrates for a SET domain lysine methyltransferase predicted by multistate computational protein design.
    Lanouette S; Davey JA; Elisma F; Ning Z; Figeys D; Chica RA; Couture JF
    Structure; 2015 Jan; 23(1):206-215. PubMed ID: 25533488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of substrate methylation and inhibition of SMYD2.
    Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
    Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
    Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of p53 activity by Smyd2-mediated methylation.
    Huang J; Perez-Burgos L; Placek BJ; Sengupta R; Richter M; Dorsey JA; Kubicek S; Opravil S; Jenuwein T; Berger SL
    Nature; 2006 Nov; 444(7119):629-32. PubMed ID: 17108971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of histone H3 and H4 post-translational modifications of esophageal squamous cell carcinoma with different invasive capabilities.
    Zhang K; Li L; Zhu M; Wang G; Xie J; Zhao Y; Fan E; Xu L; Li E
    J Proteomics; 2015 Jan; 112():180-9. PubMed ID: 25234497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.
    Kashyap MK; Harsha HC; Renuse S; Pawar H; Sahasrabuddhe NA; Kim MS; Marimuthu A; Keerthikumar S; Muthusamy B; Kandasamy K; Subbannayya Y; Prasad TS; Mahmood R; Chaerkady R; Meltzer SJ; Kumar RV; Rustgi AK; Pandey A
    Cancer Biol Ther; 2010 Oct; 10(8):796-810. PubMed ID: 20686364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
    Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
    J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
    Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
    Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain.
    Chandramouli B; Melino G; Chillemi G
    Mol Oncol; 2019 Jun; 13(6):1450-1461. PubMed ID: 31069954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.